1. Introduction {#sec1-ijerph-15-02608}
===============

The global level of particulate matter \<2.5 μm in size (PM~2.5~) rose by 11.2% from 1990 (39.7 μg/m³) to 2015 (44.2 μg/m³), and exposure to PM~2.5~ was the fifth most common cause of death in 2015 globally, resulting in the deaths of 4.2 million people \[[@B1-ijerph-15-02608]\]. Ambient air pollutants were recently classified as lung carcinogens by the International Agency for Research on Cancer of the World Health Organization (WHO) and are considered as "the most extensive environmental carcinogens" \[[@B2-ijerph-15-02608]\].

To date, three meta-analyses \[[@B3-ijerph-15-02608],[@B4-ijerph-15-02608],[@B5-ijerph-15-02608]\] have examined the association between air pollution and lung cancer mortality; in them, a 10 µg/m^3^ increase in PM~2.5~ levels increased the risk of and mortality from cancer by 9%, 9%, and 7%, respectively. However, these three meta-analyses used both incidence and mortality data of lung cancer. Importantly, there is a difference between cancer incidence and mortality, because not all patients suffering from cancer will die from the disease \[[@B6-ijerph-15-02608]\]. Recent prospective cohort data collected from 623,048 participants over 22 years showed that a 4.4 μg/m^3^ increase in PM~2.5~ levels increased kidney and bladder cancer mortality rates by 14% and 13%, respectively \[[@B7-ijerph-15-02608]\]. Nitrogen dioxide (NO~2~) was also positively linked to increased mortality from colorectal cancer in this study (hazard ratio (HR) per 6.5 parts per billion (ppb): 1.06; 95% confidence interval (CI): 1.02--1.10).

At present, there are no reported quantitative meta-analyses on the association between ambient air pollution and mortality from all types of cancers. The current study addressed this gap by performing a meta-analysis of 30 cohort studies, as well as various subgroup analyses of the factors that might influence the results.

2. Materials and Methods {#sec2-ijerph-15-02608}
========================

2.1. Data Sources and Searches {#sec2dot1-ijerph-15-02608}
------------------------------

We searched PubMed and EMBASE (a biomedical and pharmacological bibliographic database of published literature produced by Elsevier) from October 1958 to April 2018 using common keywords related to air pollutants and cancer mortality. The keywords were "air pollution", "air pollutants", "particulate matter", "nitrogen dioxide", "sulfur dioxide", and "ozone" for exposure factors and "cancer", "malignancy", and "carcinoma" for outcome factors. Additionally, we inspected the bibliographies of related articles and reviews to identify additional pertinent data.

2.2. Study Selection and Eligibility {#sec2dot2-ijerph-15-02608}
------------------------------------

We included observational articles that met the following criteria: (1) a prospective or retrospective cohort study; (2) examined the association between air pollution and mortality from any type of cancer; and (3) reported outcome measures with adjusted relative risk (RR) and 95% CI. When two or more analyses contained duplicated data or used the same participants, we included the more comprehensive analysis. We excluded the following: (1) in vivo and in vitro studies; (2) case reports, review articles, and letters; (3) studies on cancer incidence but not mortality; (4) studies with inconvertible data; and (5) studies assessing indoor, occupational, or accidental exposures to pollutants.

Using the selection criteria, three authors (H.B.K., J.Y.S., and B.P.) independently assessed the eligibility of the retrieved articles. Any disagreements among the evaluators were resolved by discussion with the help of a fourth author (Y.J.L.).

2.3. Data Extraction {#sec2dot3-ijerph-15-02608}
--------------------

Two authors (H.B.K. and B.P.) independently extracted the study characteristics from the eligible articles, which were then reviewed by a third author (Y.J.L). The extracted data included the name of the first author, publication year, type of cohort study, year in which the participants were enrolled, location of the study, means of quantifying exposure (e.g., degree of exposure, mean concentration of pollutants), number of cases, type and stage of cancer, adjusted confounding variables, and adjusted RR ratios and 95% CI.

2.4. Assessment of Methodological Quality {#sec2dot4-ijerph-15-02608}
-----------------------------------------

We used the Newcastle--Ottawa Scale (NOS) \[[@B8-ijerph-15-02608]\] to estimate the methodological quality of the studies included in our meta-analysis. The NOS is comprised of three subscales (selection of studies, comparability, and exposure), and its scores range from 0--9. There is no established cut-off point for high versus low quality; hence, we rated studies with higher than average scores as high-quality and analyzed all studies despite their score.

2.5. Main and Subgroup Analyses {#sec2dot5-ijerph-15-02608}
-------------------------------

The main analysis examined the association between long-term exposure to air pollutants and cancer mortality. Subgroup analyses assessed the effect of the following factors on cancer mortality: type of air pollutant, gender, geographical region, duration of cohort study, mean pollutant concentration according to WHO guidelines, type of cancer, stage of cancer, number of participants, methodological quality, and smoking status. Subgroup analyses were conducted separately for the two pollutants that most significantly impacted cancer mortality.

2.6. Statistical Analyses {#sec2dot6-ijerph-15-02608}
-------------------------

Because most exposure-response meta-analyses consider the relationship between air pollution and disease mortality to be linear \[[@B9-ijerph-15-02608],[@B10-ijerph-15-02608]\], our protocol also included standardized increments: a 10 μg/m^3^ increase in exposure to PM~2.5~; particulate matter \<10 μm in size (PM~10~); NO~2~, nitrogen oxides (NO~x~), and sulfur dioxide (SO~2~); and a 10 ppb increase in exposure to ozone (O~3~). We recalculated the RR for the standardized increment for each pollutant by applying the following formula \[[@B11-ijerph-15-02608]\]:$$\mathbf{R}\mathbf{R}_{\mathbf{Standardized}} = \mathbf{e}^{({\frac{\ln{({\mathbf{R}\mathbf{R}_{\mathbf{Origin}}})}}{\mathbf{Incremen}\mathbf{t}_{\mathbf{Origin}}}~ \times ~\mathbf{Incremen}\mathbf{t}_{\mathbf{Standardized}}})}~$$ where RR is the relative risk and ln is the log to the base e. If the RR was presented on a continuous scale as an interquartile range (IQR), we used the increment in IQR instead of the increments noted above.

To evaluate the association between air pollutants and cancer mortality, a pooled RR ratio and 95% CI was calculated from the adjusted RR ratio and 95% CI in each study. To test heterogeneity across studies, we used the Higgins I^2^ test to determine the percentage of total variation \[[@B12-ijerph-15-02608]\]. I^2^ was computed as follows: where *Q* is Cochran's heterogeneity statistic and *df* indicates the degrees of freedom. I^2^ values ranged from 0% (no observed heterogeneity) to 100% (maximal heterogeneity), with values \>50% indicating substantial heterogeneity \[[@B12-ijerph-15-02608]\]. A random-effects model based on the DerSimonian and Laird method was used for calculating the overall RR and 95% CI values, because populations and methodologies differed among the studies \[[@B13-ijerph-15-02608]\].

We assessed publication bias using Begg's funnel plot and Egger's test \[[@B14-ijerph-15-02608]\]. When bias was present, the funnel plot showed asymmetry or Egger's test had a *p*-value \<0.05. We used Stata SE software, version 13.1 (StataCorp, College Station, TX, USA) for the statistical analyses.

3. Results {#sec3-ijerph-15-02608}
==========

3.1. Eligible Studies {#sec3dot1-ijerph-15-02608}
---------------------

The abstracts of a total of 1302 articles were identified in the initial investigation of two databases and by hand-searching relevant bibliographies. After excluding 485 duplicated articles, two of the authors independently surveyed the eligibility of all studies and excluded an additional 712 articles that did not meet the predetermined inclusion criteria ([Figure 1](#ijerph-15-02608-f001){ref-type="fig"}). Finally, the full texts of the remaining 105 articles were inspected, of which 75 articles were excluded for the following reasons: no RR data (n = 31), air pollution not quantified (n = 14), insufficient exposure and outcome data (n = 8), a categorical range of air pollutants was used (n = 8), population sharing (n = 7), no mortality rates for cancer (n = 5), cancer incidence was used as an outcome measurement (n = 1), and smoking status was used as a co-exposure factor (n = 1). The remaining 30 cohort studies were included in the meta-analysis \[[@B7-ijerph-15-02608],[@B15-ijerph-15-02608],[@B16-ijerph-15-02608],[@B17-ijerph-15-02608],[@B18-ijerph-15-02608],[@B19-ijerph-15-02608],[@B20-ijerph-15-02608],[@B21-ijerph-15-02608],[@B22-ijerph-15-02608],[@B23-ijerph-15-02608],[@B24-ijerph-15-02608],[@B25-ijerph-15-02608],[@B26-ijerph-15-02608],[@B27-ijerph-15-02608],[@B28-ijerph-15-02608],[@B29-ijerph-15-02608],[@B30-ijerph-15-02608],[@B31-ijerph-15-02608],[@B32-ijerph-15-02608],[@B33-ijerph-15-02608],[@B34-ijerph-15-02608],[@B35-ijerph-15-02608],[@B36-ijerph-15-02608],[@B37-ijerph-15-02608],[@B38-ijerph-15-02608],[@B39-ijerph-15-02608],[@B40-ijerph-15-02608],[@B41-ijerph-15-02608],[@B42-ijerph-15-02608],[@B43-ijerph-15-02608]\]. All cohort studies were prospective except the study by Ancona et al. \[[@B35-ijerph-15-02608]\], which was retrospective.

3.2. Characteristics of Studies Included in the Final Analysis {#sec3dot2-ijerph-15-02608}
--------------------------------------------------------------

[Table 1](#ijerph-15-02608-t001){ref-type="table"} shows the general characteristics of the 30 cohort studies included in our meta-analysis. All studies were published between 1999 and 2017 and together comprised \>36,077,332 participants. In studies reporting age, the mean age of the participants was 57.3 years (range: 0--120 years). Regarding the type of cancer, most of them concerned lung cancer, while some of them involved all types. Mostly, the selected studies were conducted in the United States (n = 10), the Netherlands (n = 3), and China (n = 3). Adjusted variables of each study were presented in [Table A1](#ijerph-15-02608-t0A1){ref-type="table"}.

Ten studies used fixed-site monitor measurements for the exposure assessment method, while 17 studies used modeling-based assessment methods such as land-use regression or air dispersion models. All studies except three \[[@B29-ijerph-15-02608],[@B31-ijerph-15-02608],[@B35-ijerph-15-02608]\] were funded by public/governmental organizations or independent scientific foundations. The NOS scores of the studies ranged from 5 to 9; the average score was 7.7. The number of high-quality studies (NOS score ≥ 8) was 21. Data were extracted from the general population in all studies except four, which were conducted on breast cancer patients \[[@B29-ijerph-15-02608]\], lung cancer patients \[[@B37-ijerph-15-02608]\], patients with myocardial infarction \[[@B40-ijerph-15-02608]\], and liver cancer patients \[[@B43-ijerph-15-02608]\], respectively.

3.3. Overall Meta-Estimates and Publication Bias {#sec3dot3-ijerph-15-02608}
------------------------------------------------

All-cancer mortality significantly correlated with long-term exposure to PM~2.5~ (RR: 1.17; 95% CI: 1.11--1.24; I^2^: 97.4%), PM~10~ (RR: 1.09; 95% CI: 1.04--1.14; I^2^: 45.7%) ([Figure 2](#ijerph-15-02608-f002){ref-type="fig"}), and NO~2~ (RR: 1.06; 95% CI: 1.02--1.10; I^2^: 95.5%) ([Figure 3](#ijerph-15-02608-f003){ref-type="fig"}). Significant, although less strong, mortality associations were also observed for NO~x~ (RR: 1.03; 95% CI: 1.00--1.07; I^2^: 0.0%) and SO~2~ (RR: 1.03; 95% CI: 1.00--1.05; I^2^: 56.6%). Pooled data for NO~2~ and NO~x~ indicated that air pollutants composed of nitrogen compounds significantly increased the risk of cancer mortality (RR: 1.05; 95% CI: 1.02--1.09; I^2^: 95.0%). Exposure to O~3~ reduced the risk estimate, albeit not to a significant extent (RR: 0.98; 95% CI: 0.90--1.07; I^2^: 74.5%; not shown in figure). In [Table A2](#ijerph-15-02608-t0A2){ref-type="table"}, a stratified analysis showed no publication bias in terms of the results for PM~2.5~, PM~10~, and NO~2~ (Egger's test for asymmetry: *p* = 0.40, 0.68, and 0.41, respectively; Begg's funnel plots were all symmetrical).

3.4. Subgroup Analyses of the Association between PM~2.5~ and Cancer Mortality {#sec3dot4-ijerph-15-02608}
------------------------------------------------------------------------------

The significant relationship between PM~2.5~ and cancer mortality was very similar in the subgroup analyses stratified by gender, geographical region, follow-up period, mean levels of pollutant concentration, stage of cancer, number of participants, methodological quality, and smoking status.

As shown in [Table 2](#ijerph-15-02608-t002){ref-type="table"}, long-term exposure to PM~2.5~ increased mortality from liver cancer, colorectal cancer, bladder cancer, and kidney cancer, as well as mortality from lung cancer. There was a similar association between PM~2.5~ and mortality from non-lung cancer (RR: 1.16, 95% CI: 1.04--1.30) when compared with mortality from lung cancer (RR: 1.14, 95% CI: 1.07--1.21). In addition, early stage cancer was more prominent in relation to air pollution and cancer mortality (RR: 1.81, 95% CI: 1.63--2.01 for localized state; RR: 1.47, 95% CI: 1.36--1.59 for regional state; and RR: 1.17, 95% CI: 1.05--1.30, for metastatic state, respectively).

3.5. Subgroup Analyses of the Association between PM~10~ and Cancer Mortality {#sec3dot5-ijerph-15-02608}
-----------------------------------------------------------------------------

Long-term exposure to PM~10~ significantly correlated with cancer mortality in subgroup analyses stratified by mean pollutant concentration, cancer stage, methodological quality, and smoking status. As shown in [Table 2](#ijerph-15-02608-t002){ref-type="table"}, it increased the mortality rate in pancreas cancer, larynx cancer, and lung cancer. However, PM~10~ was not related to mortality from cancers other than lung cancer, in contrast to PM~2.5~. Similar to PM~2.5~, PM~10~ best correlated with mortality in early-stage cancer.

PM~10~, unlike PM~2.5~, did not adversely affect mortality rates in men, women, patients in Europe, patients with follow-up periods \<10 years, and a small study size.

4. Discussion {#sec4-ijerph-15-02608}
=============

Our meta-analysis of 30 cohort studies involved \>1.0 million cases in 14 countries and hence provided sufficient statistical power. It showed that ambient air pollution significantly correlated with cancer mortality in analyses including all participants, as well as those stratified for various factors. Among the pollutants examined, PM~2.5~, PM~10~, or NO~2~ were most strongly associated with cancer mortality, whereas O~3~ was not significantly associated.

The deleterious effects of air pollution on survival were not limited to the lungs, but also included non-lung organs, especially in cancer patients exposed to PM~2.5~. Evidence from several in vivo studies suggests that particulate pollutants can travel to the liver, kidneys, and brain \[[@B44-ijerph-15-02608],[@B45-ijerph-15-02608],[@B46-ijerph-15-02608]\]. Our study indicates that air pollution is more strongly linked to cancer mortality in early-stage patients than those in later stages. Although many clinicians presume that the opposite is true, current research shows that patients in earlier stages of cancer may require more education regarding air pollution exposure prevention.

How air pollution increases cancer mortality rates is unclear, but two mechanisms have been proposed. The first mechanism involves DNA damage due to oxidative stress. Reactive oxygen species cause oxidative stress and are generated in response to PM \[[@B47-ijerph-15-02608]\]. Nitrogen pollutants can exacerbate the effects of oxidative stress on the progression of breast, prostate, colorectal, cervical, and other cancers \[[@B48-ijerph-15-02608]\]. Exposure to SO₂ is extremely harmful, as it induces oxidative stress in many organs \[[@B49-ijerph-15-02608]\]. Undue oxidative stress in cancer cells may seriously affect survival outcomes by promoting cell proliferation, genetic instability, and mutations \[[@B50-ijerph-15-02608]\]. In a prospective cohort study from the United States that included 30,239 Caucasian and African-American participants, there was a significant association between an oxidative stress and cancer mortality \[[@B51-ijerph-15-02608]\].

The second mechanism involves inflammation. In an in vitro study, inhaled gaseous and particulate pollutants increased the production of proinflammatory cytokines such as interleukin (IL)-6 and IL-8 \[[@B52-ijerph-15-02608]\]. In a cohort panel study conducted in the United States, exposure to NO~x~ and PM increased plasma IL-6 levels over a 12-week period \[[@B53-ijerph-15-02608]\]. The poor prognosis of gastric cancer and non-Hodgkin's lymphoma has been linked to excessive amounts of the proinflammatory cytokines tumor necrosis factor and IL-1, respectively \[[@B54-ijerph-15-02608],[@B55-ijerph-15-02608]\]. Furthermore, the production of tumor-associated macrophages, which occurs during the inflammatory reaction, is a sign of an exacerbated cancer state \[[@B56-ijerph-15-02608]\]. Thus, inflammation caused by exposure to air pollution may result in cancer mortality.

Unlike the other pollutants in our study, O~3~ did not significantly impact lung cancer and brain cancer survival. Similarly, in the meta-analysis conducted by Atkinson et al. on lung cancer only \[[@B57-ijerph-15-02608]\], there was no association between long-term exposure to O~3~ and lung cancer mortality (RR: 0.95; 95% CI: 0.83--1.08; I^2:^: 55%). Nonetheless, evaluating this relationship is challenging. O~3~ is comprised of a combination of noxious air elements termed the "photochemical cocktail", and its mechanisms of formation and destruction differ from those of other pollutants \[[@B58-ijerph-15-02608]\].

The key strengths of our meta-analysis are its inclusion of all cancer types, its separation of cancer mortality from cancer incidence, and its coverage of more countries and cases than previous studies. It also included more factors in its subgroup analyses than did the three previous meta-analyses that assessed the association between air pollution and lung cancer risk \[[@B3-ijerph-15-02608],[@B4-ijerph-15-02608],[@B5-ijerph-15-02608]\]. Furthermore, unlike previous studies, it examined the impact of air pollution on non-lung cancer mortality as well as lung cancer mortality. Overall, it provided the most comprehensive information to date on the mortality risk of cancer patients exposed to the main air pollutants.

The limitations of the current study include (1) no distinction between urban and rural areas; (2) considerable heterogeneity as indicated by the Higgins I^2^ values; (3) no information about indoor air pollution caused by heating, cooking, and passive smoking; (4) inclusion of only one or two studies in most cancer subgroups (lung and breast cancers were the exceptions); and (5) no data on confounding factors such as physical activity, X-ray testing, and radon exposure \[[@B59-ijerph-15-02608]\].

5. Conclusions {#sec5-ijerph-15-02608}
==============

Our data showing a robust association between air pollution and all-cancer mortality have important implications for public health. This association applied to almost all of the pollutants examined in the study and was strongest for particulate pollutants in the regions wherein their mean concentrations were below standard levels. Similarly, a recent cohort study in the United States with \>60 million participants found that exposure to PM~2.5~ increased all-cause mortality rates at concentrations below the present national limits \[[@B60-ijerph-15-02608]\]. Hence, rigorous environmental health policies are needed to keep air pollution levels, and consequently cancer mortality rates, as low as possible. Additionally, our results show that different types of PM increase the mortality rates for different types of non-lung cancers (PM~2.5~: liver, colorectal, bladder, and kidney; PM~10~: pancreas and larynx); hence, they may act via different mechanisms. Future research should focus on the association between certain types of pollutants and mortality from organ- and type-specific cancers.
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###### 

Adjusted variables of each study.

  Study                                                    Adjusted Variables
  -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Abbey et al. (1999) \[[@B15-ijerph-15-02608]\]           Education, smoking status, and alcohol use
  Hoek et al. (2002) \[[@B16-ijerph-15-02608]\]            Age, sex, smoking status, education, occupation, SEP, BMI, alcohol consumption, total fat intake, vegetable consumption, and fruit consumption
  Nafstad et al. (2004) \[[@B17-ijerph-15-02608]\]         Age, education, smoking habits, leisure-time physical activity, occupation, and risk groups for cardiovascular diseases
  Filleul et al. (2005) \[[@B18-ijerph-15-02608]\]         Age; sex; smoking habits; educational level; BMI; and occupational exposure to dust, gases, and fumes
  Boldo et al. (2006) \[[@B19-ijerph-15-02608]\]           Not available
  Brunekreef et al. (2009) \[[@B20-ijerph-15-02608]\]      Age, sex, and smoking status
  McKean-Cowdin et al. (2009) \[[@B21-ijerph-15-02608]\]   Age, sex, race, education level, number of colds in the past year, family history of brain cancer, previous radium treatment, number of head/neck X-rays, and use of vitamins
  Cao et al. (2010) \[[@B22-ijerph-15-02608]\]             Age, sex, BMI, physical activity, education, smoking status, age at starting to smoke, years smoked, cigarettes per day, alcohol intake, and hypertension
  Poppe CA et al. (2011) \[[@B23-ijerph-15-02608]\]        Age, sex, smoking status, education, marital status, BMI, alcohol consumption, occupational exposures, and diet
  Hart et al. (2011) \[[@B24-ijerph-15-02608]\]            Age, calendar year, decade of hire, region of residence, race, ethnicity, census region of residence, the healthy worker survivor effect, and years of work in each of the job groups
  Katanoda et al. (2011) \[[@B25-ijerph-15-02608]\]        Age, sex, smoking status, pack-years, smoking status of family members living together, daily green and yellow vegetable consumption, daily fruit consumption, and use of indoor charcoal or briquette braziers for heating
  Lipsett et al. (2011) \[[@B26-ijerph-15-02608]\]         Age, race, smoking status, total pack-years, BMI, marital status, alcohol consumption, second-hand smoke exposure at home, dietary fat, dietary fiber, dietary calories, physical activity, menopausal status, hormone therapy use, family history of MI or stroke, blood pressure medication, aspirin use, and contextual variables (income, income inequality, education, population size, racial composition, and unemployment)
  Lepeule et al. (2012) \[[@B27-ijerph-15-02608]\]         Age, sex, time in the study, BMI, education, and smoking history
  Hales et al. (2013) \[[@B28-ijerph-15-02608]\]           Age, sex, ethnicity, social deprivation, income, education, smoking history, and ambient temperature
  Hu et al. (2013) \[[@B29-ijerph-15-02608]\]              Age, race, marital status, cancer stage, year diagnosed, education, income, and accessibility to medical resources
  Carey et al. (2013) \[[@B30-ijerph-15-02608]\]           Age, sex, smoking, BMI, and education
  Cesaroni et al. (2013) \[[@B31-ijerph-15-02608]\]        Sex, marital status, place of birth, education, occupation, and SEP
  Heinrich et al. (2013) \[[@B32-ijerph-15-02608]\]        Educational level and smoking history
  Yorifuji et al. (2013) \[[@B33-ijerph-15-02608]\]        Age, sex, smoking category, BMI, hypertension, diabetes, financial capability, and area mean income
  Fischer et al. (2015) \[[@B34-ijerph-15-02608]\]         Age, sex, marital status, region of origin, standardized household income, and neighborhood social status
  Ancona et al. (2015) \[[@B35-ijerph-15-02608]\]          Age, gender, education, occupation, civil status, area-based SEP index, and outdoor nitrogen dioxide (NO~2~) concentration
  Chen et al. (2016) \[[@B36-ijerph-15-02608]\]            Age, gender, marital status, education, BMI, smoking status, alcohol consumption, occupational exposures, and leisure exercise
  Eckel et al. (2016) \[[@B37-ijerph-15-02608]\]           Age, sex, race/ethnicity, marital status, education index, SEP, rural-urban commuting area, distance to primary interstate highway, histology at diagnosis, year of diagnosis, and initial treatment
  Weichenthal et al. (2016) \[[@B38-ijerph-15-02608]\]     Age, sex, aboriginal ancestry, visible minority status, immigrant status, marital status, highest level of education, employment status, occupational classification, and household income
  Wong et al. (2016) \[[@B39-ijerph-15-02608]\]            Age, gender, BMI, smoking status, exercise frequency, education level, and personal monthly expenditure
  Cohen et al. (2016) \[[@B40-ijerph-15-02608]\]           Age, sex, ethnicity, SEP, obesity at baseline, and smoking status
  Guo et al. (2017) \[[@B41-ijerph-15-02608]\]             None
  Pun et al. (2017) \[[@B42-ijerph-15-02608]\]             Race, smoking, diabetes, BMI, alcohol consumption, asthma, and median income
  Deng et al. (2017) \[[@B43-ijerph-15-02608]\]            Age, sex, race/ethnicity, marital status, SEP, RUCA, distance to primary interstate highway, month and year of diagnosis, and initial treatments
  Turner et al. (2017) \[[@B7-ijerph-15-02608]\]           Age, race/ethnicity, gender, education, marital status, BMI, smoking status, passive smoking, vegetable/fruit/fiber consumption, fat consumption, alcohol consumption, industrial exposures, occupation dirtiness index, and 1990 ecological covariates

Abbreviations: BMI, body mass index; MI, myocardial infarction; RUCA, rural--urban commuting area; SEP, socio-economic position.
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###### 

Assessment of publication bias using Begg's funnel plot and Egger's test.

  Air Pollutants   *p*-Value from Egger's Test   Begg's Funnel Plot
  ---------------- ----------------------------- --------------------
  **PM~2.5~**      0.40                          Symmetry
  **PM~10~**       0.68                          Symmetry
  **NO~2~**        0.41                          Symmetry

Abbreviations: NO~2~, nitrogen dioxide; PM, particulate matter.

![Flow diagram for identification of relevant studies.](ijerph-15-02608-g001){#ijerph-15-02608-f001}

![Mortality from cancer according to long-term exposure to particulate matter (PM) in a random-effects meta-analysis of observational studies. RR, relative risk; CI, confidence interval (RR and 95% CI are for a 10 μg/m^3^ increase in PM~2.5~ and PM~10~).](ijerph-15-02608-g002){#ijerph-15-02608-f002}

![Mortality from cancer according to long-term exposure to nitrogen dioxide (NO~2~) and nitrogen oxides (NO~x~) in a random-effects meta-analysis of observational studies. RR, relative risk; CI, confidence interval (RR and 95% CI are for a 10 μg/m^3^ increase in NO~2~ and NO~x~).](ijerph-15-02608-g003){#ijerph-15-02608-f003}
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###### 

General characteristics of the cohort studies included in the final analysis (n = 30).

  References (Publication Year)                            Type of Cohort Study   Country          Years Enrolled   Number of Cases   Cancer Site   Definition of Pollutant Exposure (Incremental Increase)   RR (95% CI)         Quality Assessment (Newcastle--Ottawa Stars)
  -------------------------------------------------------- ---------------------- ---------------- ---------------- ----------------- ------------- --------------------------------------------------------- ------------------- ----------------------------------------------
  Abbey et al. (1999) \[[@B15-ijerph-15-02608]\]           Prospective            USA              1977--1992       29 cases          Lung          PM~10~ 24.08 µg/m^3^ increase                             3.36 (1.57--7.19)   8
  Hoek et al. (2002) \[[@B16-ijerph-15-02608]\]            Prospective            Netherlands      1986--1994       244 cases         Non-lung      NO~2~ 30 µg/m^3^ increase                                 1.08 (0.63--1.85)   9
  Nafstad et al. (2004) \[[@B17-ijerph-15-02608]\]         Prospective            Norway           1972--1998       382 cases         Lung          NO~x~ 10 µg/m^3^ increase                                 1.11 (1.03--1.19)   8
  Filleul et al. (2005) \[[@B18-ijerph-15-02608]\]         Prospective            France           1974--2000       178 cases         Lung          NO~2~ 10 µg/m^3^ increase                                 1.48 (1.05--2.06)   9
  Boldo et al. (2006) \[[@B19-ijerph-15-02608]\]           Prospective            Spain            1999--2003       1901 cases        Lung          PM~2.5~ 15 µg/m^3^ increase                               1.14 (1.04--1.23)   5
  Brunekreef et al. (2009) \[[@B20-ijerph-15-02608]\]      Prospective            Netherlands      1987--1996       1935 cases        Lung          PM~2.5~ 10 µg/m^3^ increase                               1.06 (0.82--1.38)   8
  McKean-Cowdin et al. (2009) \[[@B21-ijerph-15-02608]\]   Prospective            USA              1982--1988       1284 cases        Brain         PM~2.5~ 10 µg/m^3^ increase                               0.91 (0.74--1.11)   8
  Cao et al. (2010) \[[@B22-ijerph-15-02608]\]             Prospective            China            1991--2000       624 cases         Lung          SO~2~ 10 µg/m^3^ increase                                 1.04 (1.02--1.06)   8
  Poppe CA et al. (2011) \[[@B23-ijerph-15-02608]\]        Prospective            USA              1983--1988       3194 cases        Lung          PM~2.5~ 10 µg/m^3^ increase                               1.14 (1.04--1.23)   8
  Hart et al. (2011) \[[@B24-ijerph-15-02608]\]            Prospective            USA              1985--2000       800 cases         Lung          PM~2.5~ 4 µg/m^3^ increase                                1.02 (0.95--1.10)   6
  Katanoda et al. (2011) \[[@B25-ijerph-15-02608]\]        Prospective            Japan            1983--1992       518 cases         Lung          PM~2.5~ 10 µg/m^3^ increase                               1.24(1.12--1.37)    8
  Lipsett et al. (2011) \[[@B26-ijerph-15-02608]\]         Prospective            USA              1996--2005       234 cases         Lung          PM~2.5~ 10 µg/m^3^ increase                               0.95 (0.70--1.28)   8
  Lepeule et al. (2012) \[[@B27-ijerph-15-02608]\]         Prospective            USA              1974--2009       350 cases         Lung          PM~2.5~ 10 µg/m^3^ increase                               1.37 (1.07--1.75)   9
  Hales et al. (2013) \[[@B28-ijerph-15-02608]\]           Prospective            New Zealand      1996--1998       1686 cases        Lung          PM~10~ 1 µg/m^3^ increase                                 1.02 (1.00--1.03)   8
  Hu et al. (2013) \[[@B29-ijerph-15-02608]\]              Prospective            USA              1999--2009       255,128 women     Breast        PM~10~ 10 µg/m^3^ increase                                1.13 (1.02--1.25)   6
  Carey et al. (2013) \[[@B30-ijerph-15-02608]\]           Prospective            United Kingdom   2003--2007       5273 cases        Lung          PM~2.5~ 1.9 µg/m^3^ increase                              1.04 (0.99--1.09)   6
  Cesaroni et al. (2013) \[[@B31-ijerph-15-02608]\]        Prospective            Italy            2001--2010       12,208 cases      Lung          PM~2.5~ 10 µg/m^3^ increase                               1.05 (1.01--1.10)   8
  Heinrich et al. (2013) \[[@B32-ijerph-15-02608]\]        Prospective            Germany          1990-2008        41 cases          Lung          PM~10~ 7 µg/m^3^ increase                                 1.84 (1.23--2.74)   8
  Yorifuji et al. (2013) \[[@B33-ijerph-15-02608]\]        Prospective            Japan            1999--2009       116 cases         Lung          NO~2~ 10 µg/m^3^ increase                                 1.20(1.03--1.40)    8
  Fischer et al. (2015) \[[@B34-ijerph-15-02608]\]         Prospective            Netherlands      2004--2011       53,735 cases      Lung          PM~10~ 10 µg/m^3^ increase                                1.26 (1.21--1.30)   8
  Ancona et al. (2015) \[[@B35-ijerph-15-02608]\]          Retrospective          Italy            2001--2010       2196 cases        All           PM~10~ 27 µg/m^3^ increase                                1.04 (0.92--1.17)   8
  Chen et al. (2016) \[[@B36-ijerph-15-02608]\]            Prospective            China            1998--2009       140 cases         Lung          PM~10~ 10 µg/m^3^ increase                                1.05 (1.03--1.06)   9
  Eckel et al. (2016) \[[@B37-ijerph-15-02608]\]           Prospective            USA              1988--2009       352,053 cases     Lung          PM~2.5~ 5.3 µg/m^3^ increase                              1.15 (1.14--1.16)   7
  Weichenthal et al. (2016) \[[@B38-ijerph-15-02608]\]     Prospective            Canada           1991--2009       3200 cases        Lung          PM~2.5~ 10 µg/m^3^ increase                               1.05 (1.00--1.10)   7
  Wong et al. (2016) \[[@B39-ijerph-15-02608]\]            Prospective            Hong Kong        1998--2011       4531 cases        All           PM~2.5~ 10 µg/m^3^ increase                               1.22 (1.11--1.34)   8
  Cohen et al. (2016) \[[@B40-ijerph-15-02608]\]           Prospective            Israel           1992--2013       105 cases         All           NO~x~ 10 ppb increase                                     1.08 (0.93--1.26)   9
  Guo et al. (2017) \[[@B41-ijerph-15-02608]\]             Prospective            China            1990--2009       315,530 cases     Lung          PM~2.5~ 10 µg/m^3^ increase                               1.08 (1.07--1.09)   5
  Pun et al. (2017) \[[@B42-ijerph-15-02608]\]             Prospective            USA              2000--2008       255,544 cases     All           PM~2.5~ 10 µg/m^3^ increase                               1.11 (1.09--1.12)   7
  Deng et al. (2017) \[[@B43-ijerph-15-02608]\]            Prospective            USA              2000--2009       20,221 cases      Liver         PM~2.5~ 10 µg/m^3^ increase                               1.18 (1.16--1.20)   8
  Turner et al. (2017) \[[@B7-ijerph-15-02608]\]           Prospective            Canada           1982--2004       43,320 cases      Non-lung      NO2 6.5 ppb increase                                      1.06 (1.02--1.10)   8

Abbreviations: CI, confidence interval; NO, nitrogen oxides; PM, particulate matter; ppb, parts per billion; RR, relative risk.
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  Subgroups                                                                                                                                                                                                                                                                                                                                                                       PM~2.5~   PM~10~                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------- ------------------- ------ --- ------------------- ------
  Gender                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Male only                                                                                                                                                                                                                                                                                                                                                                       5         1.14 (1.00, 1.29)   80.5   4   1.06 (0.93, 1.22)   69.1
  Female only                                                                                                                                                                                                                                                                                                                                                                     6         1.13 (1.05, 1.21)   32.0   6   1.03 (0.92, 1.15)   72.3
  Male and Female                                                                                                                                                                                                                                                                                                                                                                 16        1.18 (1.11, 1.25)   97.8   6   1.10 (1.05, 1.16)   94.9
  Region                                                                                                                                                                                                                                                                                                                                                                                                                                       
  America                                                                                                                                                                                                                                                                                                                                                                         11        1.18 (1.08, 1.29)   97.2   6   1.05 (1.05. 1.23)   76.5
  Europe                                                                                                                                                                                                                                                                                                                                                                          5         1.16 (1.00, 1.35)   94.9   4   1.18 (0.99, 1.41)   95.3
  Asia                                                                                                                                                                                                                                                                                                                                                                            3         1.17 (1.05, 1.30)   85.1   1   1.05 (1.03, 1.06)   NA
  Follow-up period                                                                                                                                                                                                                                                                                                                                                                                                                             
  \<10 years                                                                                                                                                                                                                                                                                                                                                                      10        1.17 (1.07, 1.27)   96.3   4   1.11 (0.96, 1.29)   89.6
  ≥10 years                                                                                                                                                                                                                                                                                                                                                                       9         1.19 (1.07, 1.32)   98.1   9   1.06 (1.03, 1.09)   82.1
  Mean levels of pollutant concentration according to the WHO guideline                                                                                                                                                                                                                                                                                                                                                                        
  Below the standard                                                                                                                                                                                                                                                                                                                                                              4         1.20 (1.04, 1.39)   98.3   1   1.16 (1.04, 1.29)   NA
  Above the standard                                                                                                                                                                                                                                                                                                                                                              12        1.18 (1.09, 1.28)   91.1   9   1.09 (1.04, 1.15)   93.1
  Types of cancer                                                                                                                                                                                                                                                                                                                                                                                                                              
  Lung cancer                                                                                                                                                                                                                                                                                                                                                                     14        1.14 (1.07, 1.21)   97.1   9   1.07 (1.03, 1.11)   83.3
  Cancers other than lung cancer                                                                                                                                                                                                                                                                                                                                                  5         1.16 (1.04, 1.30)   90.9   3   1.05 (0.99, 1.11)   44.1
  Brain cancer                                                                                                                                                                                                                                                                                                                                                                    2         1.00 (0.84, 1.19)   36.1   2   0.93 (0.83, 1.03)   0.0
  Lymphatic & hematopoietic cancer                                                                                                                                                                                                                                                                                                                                                2         1.06 (0.90, 1.25)   10.6   1   1.04 (0.93, 1.16)   NA
  Breast cancer                                                                                                                                                                                                                                                                                                                                                                   3         1.60 (0.94, 2.72)   83.4   2   1.06 (0.93, 1.21)   64.6
  Liver cancer                                                                                                                                                                                                                                                                                                                                                                    2         1.29 (1.06, 1.58)   67.8   1   1.11 (0.84, 1.46)   NA
  Pancreas cancer                                                                                                                                                                                                                                                                                                                                                                 1         0.96 (0.91, 1.02)   NA     1   1.05 (1.04, 1.28)   NA
  Larynx cancer                                                                                                                                                                                                                                                                                                                                                                   1         1.09 (0.66, 1.79)   NA     1   1.27 (1.06, 1.54)   NA
  Stomach cancer                                                                                                                                                                                                                                                                                                                                                                  2         1.17 (0.83, 1.65)   73.4   1   0.99 (0.84, 1.16)   NA
  Colorectal cancer                                                                                                                                                                                                                                                                                                                                                               2         1.08 (1.00, 1.17)   0.0    1   0.87 (0.71, 1.07)   NA
  Bladder cancer                                                                                                                                                                                                                                                                                                                                                                  1         1.32 (1.07, 1.60)   NA     1   1.17 (0.88, 1.57)   NA
  Kidney cancer                                                                                                                                                                                                                                                                                                                                                                   1         1.35 (1.07, 1.72)   NA     1   1.03 (0.84, 1.26)   NA
  Stage of cancer                                                                                                                                                                                                                                                                                                                                                                                                                              
  Localized                                                                                                                                                                                                                                                                                                                                                                       3         1.81 (1.63, 2.01)   74.0   2   1.20 (1.12, 1.28)   45.1
  Regional                                                                                                                                                                                                                                                                                                                                                                        3         1.47 (1.36, 1.59)   55.2   2   1.12 (1.11, 1.13)   0.0
  Metastasis                                                                                                                                                                                                                                                                                                                                                                      3         1.17 (1.05, 1.30)   71.2   2   1.08 (1.02, 1.14)   49.3
  No. of participants                                                                                                                                                                                                                                                                                                                                                                                                                          
  Small (\<100,000) \[[@B15-ijerph-15-02608],[@B16-ijerph-15-02608],[@B17-ijerph-15-02608],[@B18-ijerph-15-02608],[@B22-ijerph-15-02608],[@B24-ijerph-15-02608],[@B25-ijerph-15-02608],[@B27-ijerph-15-02608],[@B32-ijerph-15-02608],[@B33-ijerph-15-02608],[@B35-ijerph-15-02608],[@B36-ijerph-15-02608],[@B39-ijerph-15-02608],[@B40-ijerph-15-02608]\]                         5         1.22 (1.15, 1.30)   0.0    6   1.05 (0.97, 1.13)   77.0
  Large (\>100,000) \[[@B7-ijerph-15-02608],[@B19-ijerph-15-02608],[@B20-ijerph-15-02608],[@B21-ijerph-15-02608],[@B23-ijerph-15-02608],[@B28-ijerph-15-02608],[@B29-ijerph-15-02608],[@B30-ijerph-15-02608],[@B31-ijerph-15-02608],[@B34-ijerph-15-02608],[@B37-ijerph-15-02608],[@B38-ijerph-15-02608],[@B41-ijerph-15-02608],[@B42-ijerph-15-02608],[@B43-ijerph-15-02608]\]   14        1.17 (1.10, 1.24)   98.1   6   1.11 (1.02, 1.21)   92.8
  Methodological quality                                                                                                                                                                                                                                                                                                                                                                                                                       
  Low quality (\<8)                                                                                                                                                                                                                                                                                                                                                               9         1.14 (1.06, 1.22)   98.1   4   1.09 (1.08, 1.10)   0.0
  High quality (≥8)                                                                                                                                                                                                                                                                                                                                                               10        1.20 (1.08, 1.33)   93.5   8   1.10 (1.01, 1.21)   94.2
  Smoking status                                                                                                                                                                                                                                                                                                                                                                                                                               
  Non-smokers                                                                                                                                                                                                                                                                                                                                                                     3         1.14 (1.01, 1.28)   0.0    1   1.66 (1.22, 2.28)   NA
  Ex-smokers                                                                                                                                                                                                                                                                                                                                                                      3         1.47 (1.17, 1.84)   51.4                           
  Current smokers                                                                                                                                                                                                                                                                                                                                                                 2         1.33 (1.20, 1.49)   0.0                            

NA, not applicable; PM, particulate matter; RR, relative risk; WHO, world health organization.
